A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

This is a Phase I clinical trial testing a new antibody drug given by injection under the skin for people with primary membranous nephropathy — a kidney disease where the immune system attacks the kidney's filtering units, causing protein to leak into the urine. The drug targets a protein called CD20 found on certain immune cells (B cells) that drive this autoimmune attack. This trial tests whether the drug is safe and how the body responds to it. **You may be eligible if...** - You are between 18 and 75 years old - You have primary membranous nephropathy confirmed by kidney biopsy - Your blood pressure is reasonably controlled (systolic 140 mmHg or below, diastolic 90 mmHg or below) - If you take blood pressure medications (ACE inhibitors or ARBs), you have been on a stable dose for at least 4 weeks - You are able to follow the study protocol **You may NOT be eligible if...** - Your membranous nephropathy is caused by another condition (secondary type) - You have had uncontrolled blood pressure in the past 3 months - Your urine protein has already dropped by 50% or more in the past 6 months - You are currently on dialysis or receiving kidney replacement therapy - You have type 1 or diabetic type 2 kidney disease - You have a history of active tuberculosis or current serious infection - You have had a live vaccine, major surgery, or another clinical trial within the past 28 days - You are pregnant, breastfeeding, or not using adequate contraception - You have hepatitis B, hepatitis C, or a history of immune deficiency **Talk to your doctor if** you have been diagnosed with membranous nephropathy and are looking for treatment options beyond standard medications.